CDC25A and neoplasm: In summary, YBX1 promotes tumor progression through its transcription factor activity, exerting its effects via various downstream targets such as MUC1, CDC25a, NANOG, Kindlin-2, G3BP1, AURKA, SPP1, the EGFR-RAS-MAPK axis, CORO1C, among others, depending on the specific tumor type.